11 – 20 of 134
- show: 10
- |
- sort: year (new to old)
Close
Embed this list
<iframe src=""
width=""
height=""
allowtransparency="true"
frameborder="0">
</iframe>
- 2025
-
Mark
Peripheral T- and natural killer-cell lymphomas : ESMO–EHA Clinical Practice Guideline for diagnosis, treatment and follow-up ☆
- Contribution to journal › Article
-
Mark
Limited stage mantle cell lymphoma : A real-world study of primary treatment and prognosis in Sweden 2006–2018
- Contribution to journal › Letter
-
Mark
Proteogenomic Profiling of Treatment-Naïve Metastatic Malignant Melanoma
- Contribution to journal › Article
-
Mark
Disease progression more than 6 years after treatment impacts overall survival in mantle cell lymphoma
(2025) In International Journal of Cancer
- Contribution to journal › Article
-
Mark
EHA–EU MCL network guidelines for diagnosis and treatment of mantle cell lymphoma
- Contribution to journal › Article
-
Mark
Lymphomas : ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up
- Contribution to journal › Article
-
Mark
Inter-reader agreement of quantitative FDG PET/CT biomarkers in lymphoma : a multicentre evaluation of MTV, TLG and Dmax
- Contribution to journal › Article
-
Mark
Real-world outcomes with ibrutinib in relapsed or refractory mantle cell lymphoma : a Danish population-based study
- Contribution to journal › Article
-
Mark
Ibrutinib and rituximab versus immunochemotherapy in patients with previously untreated mantle cell lymphoma (ENRICH) : a randomised, open-label, phase 2/3 superiority trial
- Contribution to journal › Article
-
Mark
Janus kinase 1 inhibitors for treating immune checkpoint inhibitor-induced enterocolitis - report of two filgotinib-treated cases and literature review
- Contribution to journal › Scientific review
